IL149104A0 - Benzodiazepine derivatives - Google Patents

Benzodiazepine derivatives

Info

Publication number: IL149104A0
Authority: IL; Israel
Prior art keywords: benzodiazepine derivatives; benzodiazepine; derivatives
Prior art date: 1999-10-15

Application number

IL14910400A

Other languages

English (en)

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-15

Filing date

2000-09-29

Publication date

2002-11-10

2000-09-29 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2002-11-10 Publication of IL149104A0 publication Critical patent/IL149104A0/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychology (AREA)
Cardiology (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Otolaryngology (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Furan Compounds (AREA)

IL14910400A 1999-10-15 2000-09-29 Benzodiazepine derivatives IL149104A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP99120519		1999-10-15
PCT/EP2000/009554 WO2001029012A2 (en)	1999-10-15	2000-09-29	Benzodiazepine derivatives as metabotropic glutamate receptor antagonists

Publications (1)

Publication Number	Publication Date
IL149104A0 true IL149104A0 (en)	2002-11-10

Family

ID=8239206

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL14910400A IL149104A0 (en)	1999-10-15	2000-09-29	Benzodiazepine derivatives
IL149104A IL149104A (en)	1999-10-15	2002-04-11	Derivatives of benzodiazepine

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL149104A IL149104A (en)	1999-10-15	2002-04-11	Derivatives of benzodiazepine

Country Status (36)

Country	Link
US (4)	US6509328B1 (sh)
EP (1)	EP1224175B1 (sh)
JP (1)	JP3886805B2 (sh)
KR (1)	KR100481386B1 (sh)
CN (1)	CN1199954C (sh)
AR (1)	AR026028A1 (sh)
AT (1)	ATE261945T1 (sh)
AU (1)	AU779874B2 (sh)
BR (1)	BR0014761A (sh)
CA (1)	CA2386980C (sh)
CO (1)	CO5251454A1 (sh)
CZ (1)	CZ20021663A3 (sh)
DE (1)	DE60009116T2 (sh)
DK (1)	DK1224175T3 (sh)
ES (1)	ES2215738T3 (sh)
GC (1)	GC0000207A (sh)
HK (1)	HK1051037A1 (sh)
HR (1)	HRP20020260B1 (sh)
HU (1)	HUP0203294A3 (sh)
IL (2)	IL149104A0 (sh)
JO (1)	JO2299B1 (sh)
MA (1)	MA26832A1 (sh)
MX (1)	MXPA02003740A (sh)
MY (1)	MY125506A (sh)
NO (1)	NO20021691D0 (sh)
NZ (1)	NZ518037A (sh)
PE (1)	PE20010759A1 (sh)
PL (1)	PL357433A1 (sh)
PT (1)	PT1224175E (sh)
RU (1)	RU2257382C2 (sh)
SI (1)	SI1224175T1 (sh)
TR (1)	TR200201026T2 (sh)
TW (1)	TWI254044B (sh)
WO (1)	WO2001029012A2 (sh)
YU (1)	YU27902A (sh)
ZA (1)	ZA200202654B (sh)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2257382C2 (ru)	1999-10-15	2005-07-27	Ф.Хоффманн-Ля Рош Аг	Производные бензодиазепина, лекарственное средство, содержащее их, и способ их получения
CA2442557C (en)	2001-04-12	2008-12-23	F. Hoffmann-La Roche Ag	Dihydro-benzo¬b\|¬1,4\|diazepin-2-one derivatives as mglur2 antagonists ii
RU2270197C2 (ru) *	2001-04-12	2006-02-20	Ф.Хоффманн-Ля Рош Аг	ПРОИЗВОДНЫЕ ДИГИДРОБЕНЗО[b][1,4]ДИАЗЕПИН-2-ОНА В КАЧЕСТВЕ АНТАГОНИСТОВ I mGluR2
US6949542B2 (en) *	2002-02-06	2005-09-27	Hoffman-La Roche Inc.	Dihydro-benzo[b][1,4]diazepin-2-one derivatives
US7531529B2 (en) *	2003-06-05	2009-05-12	Roche Palo Alto Llc	Imidazole derivatives
ES2293287T3 (es) *	2003-07-25	2008-03-16	F. Hoffmann-La Roche Ag	Combinacion de antagonista de mglur2 y de inhibidor de ache para el tratamiento de trastornos neurologicos agudos y/o cronicos.
BRPI0511678A (pt)	2004-06-01	2008-01-08	Hoffmann La Roche	piridin-4-il-etinil-imidazóis e pirazóis como antagonistas de receptor de mglu5
EP1812392B1 (en)	2004-11-05	2008-07-09	F.Hoffmann-La Roche Ag	Process for preparation of isonicotinic acid derivatives
EP2258359A3 (en)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (ja)	2005-08-26	2009-02-12	ブレインセルス，インコーポレイティド	ムスカリン性受容体調節による神経発生
WO2007047978A2 (en)	2005-10-21	2007-04-26	Braincells, Inc.	Modulation of neurogenesis by pde inhibition
EP1942879A1 (en)	2005-10-31	2008-07-16	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
WO2007078819A2 (en) *	2005-12-16	2007-07-12	Arkema Inc.	Low surface energy block co-polymer preparation methods and applications
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
AR059898A1 (es)	2006-03-15	2008-05-07	Janssen Pharmaceutica Nv	Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
CA2651862A1 (en)	2006-05-09	2007-11-22	Braincells, Inc.	5 ht receptor mediated neurogenesis
WO2007134136A2 (en)	2006-05-09	2007-11-22	Braincells, Inc.	Neurogenesis by modulating angiotensin
CA2662491A1 (en)	2006-09-08	2008-03-13	Braincells, Inc.	Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
US20080188714A1 (en) *	2007-02-07	2008-08-07	Boston Scientific Scimed, Inc.	Electromechanical in-situ cleaning of optical elements
TW200845978A (en)	2007-03-07	2008-12-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en)	2007-03-07	2009-01-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
CN101657432B (zh)	2007-04-19	2013-04-10	弗·哈夫曼-拉罗切有限公司	二氢-苯并[b][1,4]二氮杂*-2-酮磺酰胺衍生物
EP2203439B1 (en)	2007-09-14	2011-01-26	Ortho-McNeil-Janssen Pharmaceuticals, Inc.	1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-ý1, 4'¨bipyridinyl-2'-ones
PL2200985T3 (pl)	2007-09-14	2011-12-30	Ortho Mcneil Janssen Pharmaceuticals Inc	1,3-Dipodstawione-4-(arylo-X-fenylo)-1H-pirydyn-2-ony
BRPI0816970A2 (pt) *	2007-09-14	2015-03-24	Ortho Mcneil Janssen Pharm	1,3-dissubstituídas-4-fenil-1h-piridin-2-onas
RU2492170C9 (ru)	2007-11-14	2013-12-27	Орто-Макнейл-Янссен Фармасьютикалз, Инк.	Имидазо[1,2-а]пиридиновые производные и их применение в качестве положительных аллостерических модуляторов рецепторов mglur2
US8193363B2 (en) *	2008-08-29	2012-06-05	Astrazeneca Ab	Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits
CA2735764C (en)	2008-09-02	2016-06-14	Ortho-Mcneil-Janssen Pharmaceuticals, Inc.	3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
BRPI0920354A2 (pt)	2008-10-16	2017-06-27	Addex Pharmaceuticals Sa	derivados de indol e benzomorfolina como moduladores de receptores de glutamato metabotrópicos
AU2009319387B2 (en)	2008-11-28	2012-05-10	Addex Pharma S.A.	Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
US20100216805A1 (en)	2009-02-25	2010-08-26	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
RS53075B (en)	2009-05-12	2014-04-30	Janssen Pharmaceuticals Inc.	1,2,4-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
AU2010246607B2 (en)	2009-05-12	2012-09-27	Addex Pharma S.A.	1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
MY153913A (en)	2009-05-12	2015-04-15	Janssen Pharmaceuticals Inc	7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN101891706B (zh) *	2010-04-09	2013-05-29	复旦大学	3,4-二氢苯并[f][1,4]噻氮杂*类化合物或其盐及其药物用途
WO2012015024A1 (ja)	2010-07-29	2012-02-02	大正製薬株式会社	エチニル－ピラゾール誘導体
WO2012020820A1 (ja)	2010-08-11	2012-02-16	大正製薬株式会社	ヘテロアリール－ピラゾール誘導体
WO2012062751A1 (en)	2010-11-08	2012-05-18	Janssen Pharmaceuticals, Inc.	1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CN103298809B (zh)	2010-11-08	2016-08-31	杨森制药公司	1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
PL2649069T3 (pl)	2010-11-08	2016-01-29	Janssen Pharmaceuticals Inc	Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2
CN102276592B (zh) *	2011-06-17	2013-10-16	大连理工大学	一种奥氮平有关物质及其制备方法、分析方法
EP2751095B1 (en) *	2011-08-29	2021-10-27	Sanford-Burnham Medical Research Institute	Novel benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof
MX344308B (es) *	2011-11-03	2016-12-13	Merck Sharp & Dohme	Derivados de quinolina carboxamida y quinolina carbonitrilo como moduladores alostericos negativos de mglur2, composiciones y su uso.
CN104736140A (zh)	2012-10-23	2015-06-24	霍夫曼-拉罗奇有限公司	用于治疗自闭症的mGlu2/3拮抗剂
CN102936223A (zh) *	2012-11-02	2013-02-20	江苏中丹药物研究有限公司	5-碘-2-甲基苯并咪唑的合成方法及纯化方法
JO3368B1 (ar)	2013-06-04	2019-03-13	Janssen Pharmaceutica Nv	مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar)	2013-09-06	2019-03-13	Janssen Pharmaceutica Nv	مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
PT3096790T (pt)	2014-01-21	2019-10-15	Janssen Pharmaceutica Nv	Combinações compreendendo moduladores alostéricos positivos ou agonistas ortostéricos do recetor glutamatérgico metabotrópico do subtipo 2 e seu uso
KR20220049612A (ko)	2014-01-21	2022-04-21	얀센 파마슈티카 엔.브이.	대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
BR112016021727A2 (pt)	2014-04-23	2017-08-15	Hoffmann La Roche	Antagonistas de mglu2/3 para o tratamento de incapacidades intelectuais
WO2015191630A1 (en)	2014-06-10	2015-12-17	Sanford-Burnham Medical Research Institute	Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof
CN108586447B (zh) *	2018-01-19	2021-01-29	中国人民解放军第四军医大学	一种苯二氮杂卓化合物及其制备方法和应用
CN108624674B (zh) *	2018-03-30	2020-11-24	青岛泱深生物医药有限公司	Krt73作为分子靶标在帕金森诊治中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6032775A (ja)	1983-07-30	1985-02-19	Daikin Ind Ltd	含フッ素ベンゾジアゼピン類
GB8601004D0 (en)	1986-01-16	1986-02-19	Fujisawa Pharmaceutical Co	1,5-benzodiazepine derivatives
GB9018601D0 (en)	1990-08-24	1990-10-10	Fujisawa Pharmaceutical Co	Tricyclic compounds
CA2054455A1 (en)	1990-11-23	1992-05-24	John James Delany	Substituted-2,3-dihydro-2-oxo-1,5-benzodiazepines and their use as fungicides
ATE207064T1 (de)	1992-07-29	2001-11-15	Merck Sharp & Dohme	Benzodiazepinderivate
GB9314981D0 (en)	1993-07-20	1993-09-01	Glaxo Spa	Chemical compounds
AU3414295A (en)	1994-08-19	1996-03-14	Nps Pharmaceuticals, Inc.	Methods and compounds active at metabotropic glutamate receptors useful for treatment of neurological disorders and diseases
EP0843660A1 (en) *	1995-07-31	1998-05-27	Novo Nordisk A/S	Heterocyclic compounds, their preparation and use
CZ292327B6 (cs)	1995-09-07	2003-09-17	F. Hoffmann-La Roche Ag	Derivát 4-(oxyalkoxyfenyl)-3-oxypiperidinu, způsob jeho přípravy, meziprodukt pro jeho přípravu a farmaceutický prostředek, který ho obsahuje
EP1037878A2 (en) *	1997-11-21	2000-09-27	Nps Pharmaceuticals, Inc.	Metabotropic glutamate receptor antagonists for treating central nervous system diseases
RU2257382C2 (ru)	1999-10-15	2005-07-27	Ф.Хоффманн-Ля Рош Аг	Производные бензодиазепина, лекарственное средство, содержащее их, и способ их получения
ATE250039T1 (de)	1999-10-15	2003-10-15	Hoffmann La Roche	Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
CA2442557C (en) *	2001-04-12	2008-12-23	F. Hoffmann-La Roche Ag	Dihydro-benzo¬b\|¬1,4\|diazepin-2-one derivatives as mglur2 antagonists ii
RU2270197C2 (ru) *	2001-04-12	2006-02-20	Ф.Хоффманн-Ля Рош Аг	ПРОИЗВОДНЫЕ ДИГИДРОБЕНЗО[b][1,4]ДИАЗЕПИН-2-ОНА В КАЧЕСТВЕ АНТАГОНИСТОВ I mGluR2
US6949542B2 (en) *	2002-02-06	2005-09-27	Hoffman-La Roche Inc.	Dihydro-benzo[b][1,4]diazepin-2-one derivatives

2000
- 2000-09-29 RU RU2002110107/04A patent/RU2257382C2/ru not_active IP Right Cessation
- 2000-09-29 PT PT00971302T patent/PT1224175E/pt unknown
- 2000-09-29 NZ NZ518037A patent/NZ518037A/en unknown
- 2000-09-29 CN CNB008142211A patent/CN1199954C/zh not_active Expired - Fee Related
- 2000-09-29 DE DE60009116T patent/DE60009116T2/de not_active Expired - Lifetime
- 2000-09-29 IL IL14910400A patent/IL149104A0/xx active IP Right Grant
- 2000-09-29 DK DK00971302T patent/DK1224175T3/da active
- 2000-09-29 WO PCT/EP2000/009554 patent/WO2001029012A2/en active IP Right Grant
- 2000-09-29 AU AU10204/01A patent/AU779874B2/en not_active Ceased
- 2000-09-29 KR KR10-2002-7004831A patent/KR100481386B1/ko not_active IP Right Cessation
- 2000-09-29 AT AT00971302T patent/ATE261945T1/de not_active IP Right Cessation
- 2000-09-29 JP JP2001531812A patent/JP3886805B2/ja not_active Expired - Fee Related
- 2000-09-29 CZ CZ20021663A patent/CZ20021663A3/cs unknown
- 2000-09-29 SI SI200030395T patent/SI1224175T1/xx unknown
- 2000-09-29 HU HU0203294A patent/HUP0203294A3/hu unknown
- 2000-09-29 TR TR2002/01026T patent/TR200201026T2/xx unknown
- 2000-09-29 EP EP00971302A patent/EP1224175B1/en not_active Expired - Lifetime
- 2000-09-29 CA CA2386980A patent/CA2386980C/en not_active Expired - Fee Related
- 2000-09-29 PL PL00357433A patent/PL357433A1/xx not_active Application Discontinuation
- 2000-09-29 ES ES00971302T patent/ES2215738T3/es not_active Expired - Lifetime
- 2000-09-29 MX MXPA02003740A patent/MXPA02003740A/es active IP Right Grant
- 2000-09-29 BR BR0014761-3A patent/BR0014761A/pt not_active Application Discontinuation
- 2000-09-29 YU YU27902A patent/YU27902A/sh unknown
- 2000-10-07 TW TW089121013A patent/TWI254044B/zh not_active IP Right Cessation
- 2000-10-11 GC GCP2000949 patent/GC0000207A/en active
- 2000-10-11 JO JO2000170A patent/JO2299B1/en active
- 2000-10-11 CO CO00077374A patent/CO5251454A1/es not_active Application Discontinuation
- 2000-10-12 PE PE2000001096A patent/PE20010759A1/es not_active Application Discontinuation
- 2000-10-13 US US09/687,241 patent/US6509328B1/en not_active Expired - Fee Related
- 2000-10-13 MY MYPI20004818A patent/MY125506A/en unknown
- 2000-10-13 AR ARP000105385A patent/AR026028A1/es unknown
2002
- 2002-03-27 HR HR20020260 patent/HRP20020260B1/xx not_active IP Right Cessation
- 2002-04-04 ZA ZA200202654A patent/ZA200202654B/en unknown
- 2002-04-10 NO NO20021691A patent/NO20021691D0/no not_active Application Discontinuation
- 2002-04-11 IL IL149104A patent/IL149104A/en not_active IP Right Cessation
- 2002-04-15 MA MA26602A patent/MA26832A1/fr unknown
- 2002-11-20 US US10/300,449 patent/US6960578B2/en not_active Expired - Fee Related
2003
- 2003-04-17 HK HK03102801A patent/HK1051037A1/xx not_active IP Right Cessation
2005
- 2005-06-07 US US11/146,693 patent/US7018998B2/en not_active Expired - Fee Related
2006
- 2006-02-27 US US11/363,351 patent/US7151098B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20060148791A1 (en)	2006-07-06
ATE261945T1 (de)	2004-04-15
EP1224175B1 (en)	2004-03-17
YU27902A (sh)	2004-11-25
AU1020401A (en)	2001-04-30
CA2386980C (en)	2010-03-16
BR0014761A (pt)	2002-07-02
RU2257382C2 (ru)	2005-07-27
DE60009116D1 (de)	2004-04-22
CO5251454A1 (es)	2003-02-28
PT1224175E (pt)	2004-07-30
CA2386980A1 (en)	2001-04-26
MXPA02003740A (es)	2002-09-30
US7151098B2 (en)	2006-12-19
HK1051037A1 (en)	2003-07-18
JO2299B1 (en)	2005-09-12
PL357433A1 (en)	2004-07-26
KR100481386B1 (ko)	2005-04-08
IL149104A (en)	2006-12-10
MA26832A1 (fr)	2004-12-20
TWI254044B (en)	2006-05-01
JP3886805B2 (ja)	2007-02-28
HRP20020260B1 (en)	2004-12-31
ES2215738T3 (es)	2004-10-16
US20030092677A1 (en)	2003-05-15
KR20020047237A (ko)	2002-06-21
ZA200202654B (en)	2003-09-23
MY125506A (en)	2006-08-30
NZ518037A (en)	2004-04-30
NO20021691L (no)	2002-04-10
US7018998B2 (en)	2006-03-28
US6509328B1 (en)	2003-01-21
HRP20020260A2 (en)	2004-02-29
NO20021691D0 (no)	2002-04-10
US20050234048A1 (en)	2005-10-20
DE60009116T2 (de)	2005-02-17
PE20010759A1 (es)	2001-07-19
TR200201026T2 (tr)	2002-08-21
WO2001029012A3 (en)	2001-11-08
HUP0203294A2 (hu)	2003-02-28
AU779874B2 (en)	2005-02-17
AR026028A1 (es)	2002-12-26
DK1224175T3 (da)	2004-07-12
CZ20021663A3 (cs)	2002-09-11
US6960578B2 (en)	2005-11-01
CN1199954C (zh)	2005-05-04
GC0000207A (en)	2006-03-29
SI1224175T1 (en)	2004-08-31
EP1224175A2 (en)	2002-07-24
CN1379764A (zh)	2002-11-13
JP2003512360A (ja)	2003-04-02
WO2001029012A2 (en)	2001-04-26
HUP0203294A3 (en)	2003-03-28

Publication	Publication Date	Title
GC0000207A (en)	2006-03-29	Benzodiazepine derivatives
EG24079A (en)	2008-05-11	Benzodiazepine derivatives
EG23817A (en)	2007-09-19	4-Phenyl-pyridine derivatives
HUP0201535A2 (en)	2002-08-28	5-cyano-2-aminopyrimidine derivatives
IL148167A0 (en)	2002-09-12	Amino-triazolopyridine derivatives
GC0000183A (en)	2006-03-29	3-Phenyl-pyridine derivatives
IL145739A0 (en)	2002-07-25	13-methyl-erythromycin derivatives
GC0000338A (en)	2007-03-31	5-Phenyl-pyrimidine derivatives
IL148837A0 (en)	2002-09-12	Isoxazolecarboxamide derivatives
GC0000191A (en)	2006-03-29	4-Phenyl-pyrimidine derivatives
IL155035A0 (en)	2003-10-31	Benzodiazepine derivatives
GB0026485D0 (en)	2000-12-13	›-Carboline derivatives
GC0000256A (en)	2006-11-01	Ethanesulfonyl-piperidine derivatives
IL147636A0 (en)	2002-08-14	3-amino-2-benzyl-1-phenyl-propane derivatives
IL150132A0 (en)	2002-12-01	Cyclopenteneone derivatives
IL145949A0 (en)	2002-07-25	1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives
PL351407A1 (en)	2003-04-22	Thio-oxindole derivatives
IL146282A0 (en)	2002-07-25	Thio-oxindole derivatives
GB9907134D0 (en)	1999-05-19	Antimor napthylcombretastatin derivatives
HK1043987A1 (zh)	2002-10-04	硫-羥吲衍生物

Legal Events

Date	Code	Title	Description
2007-07-06	KB	Patent renewed
2007-07-24	FF	Patent granted